文献速递免疫规划传染病防控与疫情报告

HIV阳性人群的流感疫苗接种:系统综述与网状Meta分析

Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis.
PubMed 文献 · Vaccine · 2018-05-30

该研究检索1946年至2015年7月的随机对照试验,纳入13项RCT,采用贝叶斯网状Meta分析比较HIV阳性成人不同流感疫苗策略的血清转化与血清保护效果。结果显示,佐剂7.5 μg加强策略和60 μg单剂策略在血清转化和血清保护结局上表现更优。

要点

  • 纳入13项RCT,比较HIV阳性成人不同流感疫苗策略的血清转化与血清保护结局。
  • 与15 μg单剂策略相比,佐剂7.5 μg加强策略在H1N1血清转化上OR为2.99(95%可信区间1.18-7.66)。
  • 60 μg单剂策略在B株血清转化上OR为2.33(95%可信区间1.31-4.18)。

核心结论

  • 佐剂7.5 μg加强策略和60 μg单剂疫苗策略提供了更好的血清转化和血清保护结局。

研究设计与样本

  • 系统综述与贝叶斯网状Meta分析,检索MEDLINE、EMBASE、Cochrane对照试验中心注册库、Cochrane系统综述数据库和CINAHL于1946年至2015年7月间收录的随机对照试验。

主要发现

  • 共鉴定1957篇文献,143篇进入全文审查,最终纳入13项RCT。
  • 按结局、疫苗株和不同结局测量时间点共进行14项独立的网状Meta分析。
  • 与15 μg单剂疫苗策略相比,佐剂7.5 μg加强策略在末次接种后14-41天H1N1血清转化比较中OR最高,为2.99(95%可信区间1.18-7.66)。
  • 与15 μg单剂疫苗策略相比,60 μg单剂策略在B株血清转化比较中OR为2.33(95%可信区间1.31-4.18)。

关键数值与推荐

  • 与15 μg单剂策略相比,佐剂7.5 μg加强策略的H1N1血清转化OR为2.99(95%可信区间1.18-7.66)。
  • 与15 μg单剂策略相比,60 μg单剂策略的B株血清转化OR为2.33(95%可信区间1.31-4.18)。

临床怎么用

  • 作者认为,佐剂7.5 μg加强策略和60 μg单剂疫苗策略提供了更好的血清转化和血清保护结局。
  • 作者认为,这些发现对国家和国际HIV阳性人群流感疫苗接种指南及未来研究具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with Human Immunodeficiency Virus (HIV) are highly susceptible to influenza-related morbidity and mortality. In order to assess comparative efficacy of influenza vaccine strategies among HIV-positive people, we performed a systematic review and Bayesian network meta-analysis (NMA). METHODS: In this systematic review, we searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL between 1946 and July 2015 for randomized controlled trials (RCTs) on influenza vaccines for HIV-positive adults reporting seroconversion or seroprotection outcomes. The NMAs were conducted within a Bayesian framework and logistic models were used for comparing the effect of the vaccine strategies on the two outcomes. RESULTS: A total of 1957 publications were identified, 143 were selected for full review, and 13 RCTs were included in our final analysis. Fourteen separate NMAs were conducted by outcomes, vaccine strain, and different outcome measurement timepoints. For example, compared with the 15 μg single vaccine strategy, the odds ratio was the highest for the adjuvant 7.5 μg booster strategy (2.99 [95% credible interval 1.18-7.66]) when comparing seroconversion for H1N1 at 14-41 days after the last dose of vaccination and for the 60 μg single strategy (2.33 [1.31-4.18]) when comparing seroconversion for strain B. CONCLUSIONS: The adjuvant 7.5 μg booster and 60 μg single vaccine strategies provided better seroconversion and seroprotection outcomes. These findings have important implications for national and international guidelines for influenza vaccination for HIV-positive people and future research.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang W, Sun H, Atiquzzaman M, et al. Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis. Vaccine. 2018. PMID: 29859802. doi:10.1016/j.vaccine.2018.05.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。